Ready for the Talk
"Diet, exercise, oral medications, and I’m still not controlled."
- Ready for the Talk

Your patients may be more ready to consider adding insulin to their treatment plan than you think.

You may want to have the insulin talk sooner

When it's time for the insulin talk.

Sometimes the last thing you want to bring up is what patients may need to hear

Why re-think insulin Video

Of the 25.8 million people1 in the U.S. affected by diabetes, approximately 9 million2 have blood sugar that may be uncontrolled. Help raise patient awareness about diabetes treatment options, including insulin, that may help. Learn more about the insulin initiative.

Play Video

Patient reluctance can make some discussions harder to initiate than others. Because of this, insulin may be a topic that neither you nor your patient wants to discuss. Many of your patients, however, may be more ready to consider adding insulin to their treatment plan than you think.

For patients struggling to control type 2 diabetes mellitus (T2DM) on oral antidiabetes medications (OADs) alone, adding insulin may help make a difference in lowering their blood glucose.

  • How receptive are patients to starting insulin? Learn More
  • Insulin is used to help lower blood sugar, which can help lower A1C. Learn More
  • Understand the value of timely insulin initiation. Learn More
Next >

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Please click here for full prescribing information

References: 1. American Diabetes Association Web site. Diabetes statistics. Available at:
http://www.diabetes.org/diabetes-basics/diabetes-statistics/ Accessed May 2010.
2. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Diabetes Care 2008;31:81-86.